A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

PURPOSE: To determine the toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of cediranib administered orally, once daily, continuously in children and adolescents with solid tumors. PATIENTS AND METHODS: Children and adolescents w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fox, Elizabeth, Aplenc, Richard, Bagatell, Rochelle, Chuk, Meredith K., Dombi, Eva, Goodspeed, Wendy, Goodwin, Anne, Kromplewski, Marie, Jayaprakash, Nalini, Marotti, Marcelo, Brown, Kathryn H., Wenrich, Barbara, Adamson, Peter C., Widemann, Brigitte C., Balis, Frank M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020690/
https://ncbi.nlm.nih.gov/pubmed/21060028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.9674
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados